BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
about
Practical aspects of NGS-based pathways analysis for personalized cancer science and medicineHsp90 Inhibitors for the Treatment of Chronic Myeloid LeukemiaTailoring the Treatment of Melanoma: Implications for Personalized MedicinePharmacology and rationale for imatinib in the treatment of sclerodermaKilling me softly--future challenges in apoptosis researchCIViC databaseA natural-like synthetic small molecule impairs bcr-abl signaling cascades and induces megakaryocyte differentiation in erythroleukemia cellsIdentification of Dual Natural Inhibitors for Chronic Myeloid Leukemia by Virtual Screening, Molecular Dynamics Simulation and ADMET Analysis.c-Abl inhibition delays motor neuron degeneration in the G93A mouse, an animal model of amyotrophic lateral sclerosis.Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study.Effectiveness of imatinib mesylate over etoposide in the treatment of sensitive and resistant chronic myeloid leukaemia cells in vitroThe tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cells.A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification.EgoNet: identification of human disease ego-network modulesIs Imatinib Maintenance Required for Patients with Relapse Chronic Myeloid Leukemia Post-Transplantation Obtaining CMR? A Pilot Retrospective Investigation.Berbamine inhibits proliferation and induces apoptosis of KU812 cells by increasing Smad3 activity.What is the future of targeted therapy in rheumatology: biologics or small molecules?Novel agent nitidine chloride induces erythroid differentiation and apoptosis in CML cells through c-Myc-miRNAs axis.In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study.Design of substrate-based BCR-ABL kinase inhibitors using the cyclotide scaffold.Discovery of new small molecules inhibiting 67 kDa laminin receptor interaction with laminin and cancer cell invasion(Z)3,4,5,4'-trans-tetramethoxystilbene, a new analogue of resveratrol, inhibits gefitinb-resistant non-small cell lung cancer via selectively elevating intracellular calcium level.ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan.Serum concentrations of nitrite and malondialdehyde as markers of oxidative stress in chronic myeloid leukemia patients treated with tyrosine kinase inhibitorsEffectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision AnalysisA Review of Mathematical Models for Leukemia and LymphomaChanging paradigm of cancer therapy: precision medicine by next-generation sequencing.The protein kinase promiscuities in the cancer-preventive mechanisms of NSAIDs.Imatinib and Nilotinib increase glioblastoma cell invasion via Abl-independent stimulation of p130Cas and FAK signalling.Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinibUltraviolet activation of PKD: implications for skin cancer.Cancer biomarker discovery is improved by accounting for variability in general levels of drug sensitivity in pre-clinical models.Characterization of Patients with Chronic Myeloid Leukemia Unresponsive to Tyrosine Kinase Inhibitors Who Underwent Allogeneic Hematopoietic Stem Cell TransplantationA structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.Tumor control versus adverse events with targeted anticancer therapies.Towards clinical applications of selected reaction monitoring for plasma protein biomarker studies.A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets.Differentiation therapy of acute myeloid leukemia.Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury.
P2860
Q26748603-FFA3C93C-90C0-4D75-B4BE-FD2B05C05C79Q26771790-B5DFE4F3-88CD-476E-872B-59F612B7A06DQ26775806-557D67CF-EB76-4516-AD91-0BA61281B000Q26825153-534CCD13-9F13-484D-8564-E5562C664B61Q27025213-7DF239D5-E3E5-4D42-9769-A1B44F582387Q27612411-4A58EFCB-8AFB-4AFF-A942-D86D56A86ECCQ28486933-224362E5-83F7-4928-A920-20C2339BBC54Q30009113-67E5B7F7-280E-494B-96DC-3B0EE6266552Q31104448-10AE874B-6ED9-4572-A4DC-F4F055C994FEQ33441382-2525A011-8948-4495-B763-5C713E615446Q33744180-E568100B-7B60-4B81-9EE3-8B6BF5BDB635Q34099289-4D939722-43C8-44EB-8F2E-7C9C7DE4F991Q34170309-5A4B0E0A-857D-4611-8523-F527AD512827Q34404209-58045558-FD90-4E28-A6AB-2341741A0558Q34525552-682D6D1F-E406-468C-96CC-BFC2DCD0AE72Q34792645-5007EDAF-3FD8-4333-842A-A6DA3BDBB629Q35100843-90F15845-FEAA-45C1-9B96-30F43E2D059FQ35118364-467C1CBC-C9B8-4116-B304-368253F60790Q35554311-9B875979-BC0B-47C6-A78D-EB58E27D8D7FQ35812209-FB2313FB-9E9E-4CE6-9614-02E4F4E83602Q35942258-AF463756-D874-422F-B7EF-062AF24B352DQ36228519-C97A747F-0776-4654-97FF-1860091BFBBBQ36254754-A4AA46FC-3D6A-406B-A308-172CEDEAADD0Q36353183-626845B0-3F67-4AA4-85E5-31565AF633F3Q36364835-1B925C80-E141-4670-BF82-E3636E9B567CQ36400944-7479057F-55A2-4985-81F7-692AF19623B1Q36423882-92261AAB-A0E3-4B5D-AF1A-83AC62A69483Q36849642-374D1DEA-8D22-4A26-8427-8091F31CA48FQ36947861-BC6CCA0A-670D-4CFB-AAA9-FA5BB9BB8387Q36996552-6A40C899-0487-43FB-96CC-1510317533ABQ37087238-364B161D-72E2-4259-B78E-8947F5072378Q37094286-E868A6C6-90E2-468C-A41B-5106DBF2E4FFQ37272774-C07AF7FA-9366-4DC1-B3C0-388C4E0F8D64Q37682119-A0719D26-5658-443B-A820-935275398AD7Q37921836-C9FFBF47-233D-4A3F-91CA-39BC0E57C133Q37969899-4BC394E8-DB7F-41DD-8DC2-CD1BDFD3F175Q37972865-594EE3DB-06AD-4EDB-99B0-EBF321A9A708Q37976467-7E2FBC6B-B62B-430F-9166-464FEF0AE41BQ38161360-B9DC0523-4B88-4BE4-A04C-F9EDC5760EFCQ38166071-577F8723-8559-4358-B5C9-9E3F82CAC323
P2860
BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
BCR-ABL tyrosine kinase inhibi ...... ic myeloid leukemia: a review.
@ast
BCR-ABL tyrosine kinase inhibi ...... ic myeloid leukemia: a review.
@en
BCR-ABL tyrosine kinase inhibi ...... ic myeloid leukemia: a review.
@nl
type
label
BCR-ABL tyrosine kinase inhibi ...... ic myeloid leukemia: a review.
@ast
BCR-ABL tyrosine kinase inhibi ...... ic myeloid leukemia: a review.
@en
BCR-ABL tyrosine kinase inhibi ...... ic myeloid leukemia: a review.
@nl
prefLabel
BCR-ABL tyrosine kinase inhibi ...... ic myeloid leukemia: a review.
@ast
BCR-ABL tyrosine kinase inhibi ...... ic myeloid leukemia: a review.
@en
BCR-ABL tyrosine kinase inhibi ...... ic myeloid leukemia: a review.
@nl
P2093
P3181
P1433
P1476
BCR-ABL tyrosine kinase inhibi ...... ic myeloid leukemia: a review.
@en
P2093
Amit K Tiwari
Charles R Ashby
Pei-Rong Ding
Zhe-Sheng Chen
P304
P3181
P356
10.1016/J.LEUKRES.2010.04.016
P577
2010-10-01T00:00:00Z